Inactive Instrument

Transition Therapeutics Inc Share Price

Equities

Duration

Period

Style

Transition Therapeutics : Announces Special Shareholder Meeting Voting Results Including Shareholder Approval of the Plan of Arrangement with OPKO Health, Inc.	25/08/16	PR
Transition Therapeutics : Receives Notification From NASDAQ	03/06/16	PR
Transition Therapeutics : Announces Third Quarter Fiscal 2016 Financial Results	11/05/16	PR
Transition Therapeutics to Hold Conference Call on Third Quarter Fiscal 2016 Financial Results on Wednesday, May 11th, at 4:30 P.M. EST	09/05/16	PR
Transition Therapeutics : Provides Update on Type 2 Diabetes Drug Candidate TT401	18/04/16	PR

Managers	Title	Age	Since
Antonio F. Cruz CEO	Chief Executive Officer	71	05/07/98

Members of the board	Title	Age	Since
Antonio F. Cruz CEO	Chief Executive Officer	71	05/07/98

Sector

	1st Jan change	Capi.
CSL LIMITED	-4.66%	86.13B
SAMSUNG BIOLOGICS CO.,LTD.	+1.32%	39.82B
BIOGEN INC.	-19.27%	30.42B
UCB	+57.86%	25.23B
INCYTE CORPORATION	-17.69%	11.6B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-43.00%	11.51B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-9.14%	11.95B
SWEDISH ORPHAN BIOVITRUM AB	+5.24%	8.71B
INNOVENT BIOLOGICS, INC.	-8.42%	8.12B